“Gyrolab platform is a choice for Agilex and our clients when high throughput is warranted...[or] reagent volume is of concern...in discovery/pre-clinical mouse models or rare matrices such as cerebral spinal fluid or ocular fluid”

Agilex Biolabs

Agilex Biolabs LogoThe semi-automation of Gyrolab platform has allowed us to demonstrate Agilex’s ability to produce robust immunoassays in singlicate for several biosimilar molecules. This has significantly improved throughput in our laboratory and thus the data's speed to patient for our end clients.

 

Agilex currently has a Gyrolab xPlore (1 CD) instrument, which we have had for approximately 3 years. Agilex offers bioanalytical analysis within the regulated and non-regulated spaces spanning discovery, pre-clinical, first in human, and late phase trials. We predominantly utilize the Gyrolab platform to support our Pharmacokinetic and Biomarker applications.

Advantages Gyrolab platform brings to Agilex

Gyrolab platform’s key advantages lie in its low sample volume, low matrix effects, high precision, and high throughput. We utilize these advantages to ensure we can deliver the most appropriate assay to our clients dependent on their needs, and the context of the specific assay.

Typically, Gyrolab is a choice for Agilex and our clients when high throughput is warranted. For example, in large late-stage trials or biosimilar trials where sample numbers can reach the tens of thousands. Further, we move to Gyrolab when reagent volume is of concern. For example, in discovery/pre-clinical mouse models or rare matrices such as cerebral spinal fluid or ocular fluid.

Tailoring assay requirements to clients' needs

Agilex Biolabs initially acquired the Gyrolab platform to increase our technological platforms available to clients, and to offer increased throughput in our immunoassay department. Having a large repertoire of technological platforms means we can tailor a client's needs/assay requirements to the most appropriate platform. Gyrolabs key advantages help with this overarching goal.

The semi-automation of Gyrolab platform has allowed us to demonstrate Agilex’s ability to produce robust immunoassays in singlicate for several biosimilar molecules. This has significantly improved throughput in our laboratory and thus the data's speed to patient for our end clients.

Working with Gyros Protein Technologies

We enjoy working with Gyros Protein Technologies since we find them to be accommodating, industry thought leaders, have good customer service, and open to novel ideas and collaboration.

About Agilex Biolabs

Agilex Biolabs, based in Australia, is the APAC biolabs for clinical trials working predominantly with USA and Asian biopharma companies on their drug development programs. Agilex Biolabs taps 24 years of experience in bioanalysis for small molecules and biologics for PK, PD, immunogenicity, and biomarkers as well as an immunobiology service for evaluation of immunological endpoints by flow cytometry and cell-based assays.

 

Specializing in LC-MS/MS and immunoassay/immunobiology services

The company specializes in both LC-MS/MS and immunoassay/immunobiology services and operates a fully quality-assured, FDA-inspected laboratory in Australia (ISO/IEC17025 and OECD GLP). Agilex Biolabs also offers rodent toxicology services from its NATA-accredited, GLP-recognized facility on a two-year audit cycle. Services include LC-MS/MS bioanalysis, immunoassay/immunobiology analysis, biomarkers, and toxicology.

 

Agilex engaging with biopharma

With strong biosimilar, oncology, and early phase experience, Agilex would like to engage with biopharma companies interested in utilizing Australia for their early phase clinical trials to access regulatory speed, R&D Tax refunds, premium quality service, and our 24-year track record. 

 

Watch the webinar presented by Morgan Evans, Principal Method Development Scientist, Agilex Biolabs:

 

 

 

Or, find out more at www.agilexbiolabs.com.